← Back

Nu Skin Enterprises Inc

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide through its subsidiaries. Its offerings include skin care devices, cosmetics, and personal care items such as ageLOC LumiSpa, ageLOC LumiSpa iO, Nu Skin RenuSpa iO, ageLOC TruFace, Prysm iO, and Nutricentials, as well as wellness products like ageLOC TRME, LifePak, and Beauty Focus. The company also conducts research and product development for skin care products, nutritional supplements, and devices. Products are sold under the Nu Skin, Pharmanex, and ageLOC brands via retail stores, websites, digital platforms, independent direct sellers and marketers, and a service center. It operates in Mainland China, South Korea, Southeast Asia/Pacific, the Americas, Japan, Hong Kong/Taiwan, and Europe & Africa. Founded in 1984, Nu Skin Enterprises is headquartered in Provo, Utah.

Country
Price · split & dividend adjusted
News & notes moving NUS
United States
NUS▼

Nu Skin Q2 earnings meet estimates, revenues miss and decline 17%

Nu Skin Enterprises reported second-quarter 2026 adjusted earnings of 20 cents per share, matching the Zacks Consensus Estimate but down 53.5% from 43 cents a year earlier. Quarterly revenues fell 17.1% to $320.1 million, missing the $345 million consensus, with Rhyz revenues dropping 25% to $48.9 million. The company cut its full-year 2026 revenue guidance to a range of $1.28 billion to $1.35 billion from the prior $1.35 billion to $1.50 billion, and lowered its adjusted EPS outlook to 70 to 90 cents from 80 cents to $1.20. For the third quarter, Nu Skin expects revenues of $310 million to $340 million and adjusted earnings of 10 to 20 cents per share.
NUS · Capital · Negative Q2 earnings met estimates but revenues missed and declined 17%, with guidance cut for full year.
Read original ↗
Zacks Investment Research·54dRead more →
NUS

Zacks Names Five Beauty Stocks to Buy for Second-Half 2026

Zacks Investment Research recommends five beauty and cosmetics stocks for a stable portfolio in the second half of 2026, all carrying a Zacks Rank of 1 (Strong Buy) or 2 (Buy). The picks are Estée Lauder, Helen of Troy, Nu Skin Enterprises, Kenvue, and Interparfums. Estée Lauder, the sole Strong Buy, is expected to see earnings grow 31.9% in its fiscal year ending June 2027, driven by its Profit Recovery and Growth Plan and digital expansion. Kenvue's earnings estimate has risen 5.5% over the past 60 days, with projected revenue growth of 3.2%. The other three companies face near-term revenue or earnings declines, but are supported by strategic initiatives such as portfolio optimization and channel expansion.
EL · Capital · Positive Zacks ranks Estée Lauder as Strong Buy with expected 31.9% earnings growth driven by Profit Recovery and Growth Plan and digital expansion.
KVUE · Capital · Positive Zacks ranks Kenvue as a Buy with earnings estimate up 5.5% over 60 days and projected revenue growth of 3.2%.
HELE · Capital · Neutral Zacks recommends Helen of Troy as a Buy despite near-term revenue/earnings declines, supported by strategic initiatives.
IPAR · Capital · Neutral Zacks recommends Interparfums as a Buy despite near-term revenue/earnings declines, supported by strategic initiatives.
NUS · Capital · Neutral Zacks recommends Nu Skin as a Buy despite near-term revenue/earnings declines, supported by strategic initiatives.
Read original ↗
Zacks Investment Research·96dRead more →
NUS▼3

Zacks Highlights Estee Lauder, e.l.f. Beauty, Helen of Troy and Nu Skin Amid Favorable Cosmetics Trends

Zacks Equity Research has identified The Estee Lauder Companies, e.l.f. Beauty, Helen of Troy, and Nu Skin Enterprises as cosmetics stocks worth watching, citing favorable industry trends. The Zacks Cosmetics industry is benefiting from sustained demand for skincare, makeup, fragrance, and personal care products, driven by consumers' focus on self-care and wellness. Innovation in science-backed formulations and clean beauty, along with digital engagement tools, is fueling growth, though companies face cautious spending, elevated input costs, and supply-chain uncertainties. The industry carries a Zacks Industry Rank of 107, placing it in the top 43% of over 247 industries, and its consensus earnings estimate for the current fiscal year has risen 17% since early April 2026. Estee Lauder, rated Zacks Rank #2, has a consensus EPS estimate of $2.41 and its stock gained 17.1% over the past year; Helen of Troy, also Rank #2, has an EPS estimate of $3.44 and an 8.4% gain; Nu Skin, Rank #3, has an EPS estimate of $1.00 and a 35% decline; and e.l.f. Beauty, Rank #3, saw its EPS estimate drop 8.6% to $3.30 and its stock fall 46.7%.
EL · Demand · Positive Favorable industry trends with sustained demand for skincare and cosmetics, benefiting Estee Lauder as a key player.
ELF · Capital · Negative EPS estimate dropped 8.6% and stock fell 46.7%, indicating negative earnings revision.
HELE · Demand · Positive Favorable industry trends and positive earnings estimate revision (EPS $3.44) support Helen of Troy.
NUS · Capital · Negative Stock declined 35% and EPS estimate of $1.00 reflects weak performance.
Read original ↗
Zacks Investment Research·108dRead more →